T. Rowe Price Investment Management, Inc. Crinetics Pharmaceuticals, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $163 Billion
- Q1 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 2,654,729 shares of CRNX stock, worth $119 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
2,654,729
Previous 2,417,493
9.81%
Holding current value
$119 Million
Previous $86 Million
44.47%
% of portfolio
0.08%
Previous 0.06%
Shares
5 transactions
Others Institutions Holding CRNX
# of Institutions
220Shares Held
75.8MCall Options Held
631KPut Options Held
749K-
Black Rock Inc. New York, NY5.44MShares$243 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL5.23MShares$234 Million2.68% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.95MShares$222 Million0.59% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA4.16MShares$186 Million5.55% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.82MShares$171 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.41B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...